Debashree Mukherjea
Department of Surgery,
Division of Otolaryngology,
Department of Surgery, Division of Otolaryngology
Southern Illinois University School of Medicine
Debashree Mukherjea has not added Biography.
If you are Debashree Mukherjea and would like to personalize this page please email our Author Liaison for assistance.
Expression and function of placenta growth factor: implications for abnormal placentation.
Journal of the Society for Gynecologic Investigation May, 2003 | Pubmed ID: 12759145
Essential role of Rac1/NADPH oxidase in nerve growth factor induction of TRPV1 expression.
Journal of neurochemistry Dec, 2005 | Pubmed ID: 16283857
Induction of adenosine A1 receptor expression by pertussis toxin via an adenosine 5'-diphosphate ribosylation-independent pathway.
The Journal of pharmacology and experimental therapeutics Apr, 2006 | Pubmed ID: 16322354
Activation of the adenosine A1 receptor inhibits HIV-1 tat-induced apoptosis by reducing nuclear factor-kappaB activation and inducible nitric-oxide synthase.
Molecular pharmacology Oct, 2007 | Pubmed ID: 17609415
Glial cell missing 1 regulates placental growth factor (PGF) gene transcription in human trophoblast.
Biology of reproduction May, 2008 | Pubmed ID: 18160678
Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat.
The Journal of neuroscience : the official journal of the Society for Neuroscience Dec, 2008 | Pubmed ID: 19052196
Role of beta-arrestin1/ERK MAP kinase pathway in regulating adenosine A1 receptor desensitization and recovery.
American journal of physiology. Cell physiology Jan, 2010 | Pubmed ID: 19828838
Cisplatin ototoxicity and protection: clinical and experimental studies.
The Tohoku journal of experimental medicine Nov, 2009 | Pubmed ID: 19851045
Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.
Neoplasia (New York, N.Y.) Nov, 2009 | Pubmed ID: 19881949
Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.
Antioxidants & redox signaling Sep, 2010 | Pubmed ID: 20214492
Pharmacogenomics of cisplatin-induced ototoxicity.
Pharmacogenomics Jul, 2011 | Pubmed ID: 21787192
The design and screening of drugs to prevent acquired sensorineural hearing loss.
Expert opinion on drug discovery May, 2011 | Pubmed ID: 22646075
Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.
PloS one , 2012 | Pubmed ID: 23272133
Essential Role of NADPH Oxidase-Dependent Reactive Oxygen Species Generation in Regulating MicroRNA-21 Expression and Function in Prostate Cancer.
Antioxidants & redox signaling Jul, 2013 | Pubmed ID: 23682737
Adenosine receptors: expression, function and regulation.
International journal of molecular sciences Jan, 2014 | Pubmed ID: 24477263
TRPV1: A Potential Drug Target for Treating Various Diseases.
Cells May, 2014 | Pubmed ID: 24861977
Early investigational drugs for hearing loss.
Expert opinion on investigational drugs Feb, 2015 | Pubmed ID: 25243609
Adenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea.
The Journal of neuroscience : the official journal of the Society for Neuroscience Apr, 2016 | Pubmed ID: 27053204
Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.
PloS one , 2017 | Pubmed ID: 28467474
Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity.
Cell death & disease Jul, 2017 | Pubmed ID: 28703809
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection.
Frontiers in cellular neuroscience , 2017 | Pubmed ID: 29163050
Copyright © 2024 MyJoVE Corporation. 판권 소유